These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27445002)

  • 1. The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016.
    Bex A; Ljungberg B; van Poppel H; Powles T;
    Eur Urol; 2016 Dec; 70(6):901-905. PubMed ID: 27445002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.
    Bex A; Albiges L; Ljungberg B; Bensalah K; Dabestani S; Giles RH; Hofmann F; Hora M; Kuczyk MA; Lam TB; Marconi L; Merseburger AS; Fernández-Pello S; Tahbaz R; Abu-Ghanem Y; Staehler M; Volpe A; Powles T
    Eur Urol; 2018 Dec; 74(6):805-809. PubMed ID: 30177291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it time to reconsider the role of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma?
    Braun AE; Meng MV
    J Natl Cancer Inst; 2024 Jul; 116(7):1002-1004. PubMed ID: 38777809
    [No Abstract]   [Full Text] [Related]  

  • 4. A commentary on 'The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis' [Int J Surg (2023) 109:982-994].
    Wang Q; Shi H; Sun Y; Feng W; Xu H; Wang H
    Int J Surg; 2024 Apr; 110(4):2458-2459. PubMed ID: 38668669
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Liu J; Moon D; Lawrentschuk N
    Eur Urol; 2023 Aug; 84(2):244-245. PubMed ID: 37088596
    [No Abstract]   [Full Text] [Related]  

  • 6. Exploring the feasibility of cytoreductive surgery for patients aged ≥75 years with metastatic renal cell carcinoma: A population-based study.
    Xia Y; Liu X; Xu DF; Zhao CH
    Asian J Surg; 2023 Dec; 46(12):5817-5819. PubMed ID: 37657984
    [No Abstract]   [Full Text] [Related]  

  • 7. Isolated soft tissue mass of the finger as the first presentation of oligometastatic renal cell carcinoma.
    Hopkins DT; Waters D; Manecksha RP; Lynch TH
    BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35580945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in a young adult with metastatic renal cell carcinoma.
    Nicaise EH; Yildirim A; Sheth S; Richter E; Daneshmand MA; Maithel SK; Ogan K; Bilen MA; Master VA
    CA Cancer J Clin; 2024; 74(4):323-338. PubMed ID: 38571300
    [No Abstract]   [Full Text] [Related]  

  • 9. Spontaneous regression of metastatic renal cell carcinoma after cytoreductive nephrectomy followed by relapse at 3 years.
    Malik M; Michalak M; Sigorski D; Bodnar L; Lewandowski T; Nawrocki S
    Pol Arch Intern Med; 2024 Mar; 134(3):. PubMed ID: 38348817
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
    Roussel E; Bertolo R; Ciccarese C; Marandino L; Marchioni M; Campi R; Albersen M;
    Eur Urol Oncol; 2024 Apr; 7(2):304-305. PubMed ID: 37981494
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing the survival advantage of deferred cytoreductive nephrectomy using a prediction interval.
    Hung KC; Tsai IT; Sun CK
    Int J Surg; 2024 Mar; 110(3):1832-1833. PubMed ID: 38126397
    [No Abstract]   [Full Text] [Related]  

  • 12. Making the GRADE: Providing Clinical Practice Guidance to the European Association of Urology.
    Canfield SE; Omar MI; Ribal MJ;
    Eur Urol; 2024 Apr; 85(4):405-406. PubMed ID: 36973115
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy: Scientifically Relevant or Natural Selection?
    Biswas B; Dabkara D; Ganguly S; Eswaran P; Ghosh J
    J Clin Oncol; 2017 Apr; 35(11):1265-1266. PubMed ID: 28165897
    [No Abstract]   [Full Text] [Related]  

  • 14. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
    Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
    Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
    Stewart GD; Aitchison M; Bex A; Larkin J; Lawless C; Méjean A; Nathan P; Oades G; Patard JJ; Paul J; Ravaud A; Escudier B;
    Eur Urol; 2017 Jun; 71(6):845-847. PubMed ID: 27815086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell carcinoma.
    Hsieh JJ; Purdue MP; Signoretti S; Swanton C; Albiges L; Schmidinger M; Heng DY; Larkin J; Ficarra V
    Nat Rev Dis Primers; 2017 Mar; 3():17009. PubMed ID: 28276433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone metastases from renal cell carcinoma: 4 years after aggressive surgeries and anti-angiogenic therapy.
    Nefiss M; Abid H; Gharbi MA; Bouzidi R; Teborbi A
    Clin Case Rep; 2022 Nov; 10(11):e6599. PubMed ID: 36408090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature.
    Dawsey SJ; Campbell SC; Ornstein MC
    Curr Oncol; 2021 May; 28(3):1921-1926. PubMed ID: 34065284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry.
    Poprach A; Holanek M; Chloupkova R; Lakomy R; Stanik M; Fiala O; Melichar B; Kopeckova K; Zemanova M; Kiss I; Penka I; Bohosova J; Buchler T
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum and tissue syndecan-1 levels in renal cell carcinoma.
    Niedworok C; Kempkensteffen C; Eisenhardt A; Tschirdewahn S; Rehme C; Panic A; Reis H; Baba H; Nyirády P; Hadaschik B; Kovalszky I; Szarvas T
    Transl Androl Urol; 2020 Jun; 9(3):1167-1176. PubMed ID: 32676400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.